Phase 2 Study Shows KP1077 Improves Symptoms in Idiopathic Hypersomnia

Explore the latest findings on KP1077 (serdexmethylphenidate or SDX) from a phase 2 study, presented at SLEEP 2024. Adrian Quartel, Chief Medical Officer of Zevra Therapeutic, broke down in interview how KP1077 has shown promise in significantly improving excessive daytime sleepiness, brain fog, and overall patient-reported outcomes in idiopathic hypersomnia. The trial provided insights into how to design a more extensive phase 3 study.
Key highlights:
• (00:007) Study Overview: A phase 2, proof-of-concept trial with 50 participants, split into daily and twice-daily dosing groups.
• (05:38) Main Findings: KP1077 demonstrated meaningful improvements in excessive daytime sleepiness and brain fog, with potential benefits in sleep inertia.
• (07:51) Safety Profile: The medication showed a clean safety profile with no cardiovascular issues and only transient insomnia in a few participants.
Read more on our website: www.hcplive.co...
Additional sleep content: www.hcplive.co...
🔔 Subscribe for more updates on cutting-edge research, clinical trials, and conference coverage.
💬 Comment below with your thoughts about the study.
👍 Like if you found this information helpful!
#KP1077 #IdiopathicHypersomnia #SleepResearch #ClinicalTrials #SLEEP2024 #ZevraTherapeutics #SleepMedicine